• In May 2026, Enhanced Group Inc. announced a broad partnership with Rezolve AI to power Live Enhanced, its direct-to-consumer digital telehealth platform, using Rezolve’s AI technology for medical concierge functions and data-driven personalization.
• This collaboration positions Rezolve AI’s software as core infrastructure in an emerging consumer health service, potentially extending its reach beyond retail-focused commerce applications into digital care experiences.
• Next, we’ll explore how powering Live Enhanced’s AI medical concierge platform could influence Rezolve AI’s long-term investment narrative and growth drivers.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

Rezolve AI Investment Narrative Recap

To own Rezolve AI, you have to believe its Brain Suite can become core infrastructure for AI driven commerce, with rapid revenue scaling despite ongoing losses and dilution. The Live Enhanced partnership reinforces that thesis by showing Rezolve’s tech used as the backbone of a new telehealth platform, but it does not change the near term catalyst of hitting aggressive 2026 revenue guidance or the key risk that growth expectations prove too ambitious.

In that context, Rezolve’s decision in April 2026 to confirm its US$360,000,000 revenue target for 2026 stands out. The Enhanced Group agreement supports the idea that new verticals, like consumer telehealth, could help fill that pipeline. At the same time, the company remains unprofitable, has a high price to sales multiple, and has relied on sizeable equity raises, so investors still need to weigh execution risk against the appeal of expanding use cases.

Yet against this upside story, investors should be aware that...

Rezolve AI's narrative projects $304.8 million revenue and $38.9 million earnings by 2028. This requires 285.9% yearly revenue growth and a $256.4 million earnings increase from $-217.5 million today.

Uncover how Rezolve AI's forecasts yield a $10.00 fair value, a 236% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already assuming rapid revenue growth to about US$264,700,000 by 2028 but still saw persistent losses, which is a much more cautious view than narratives focused on new partnerships and telehealth use cases, and it shows how differently you and other investors might assess Rezolve AI’s potential after this news.

Explore 11 other fair value estimates on Rezolve AI - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Rezolve AI research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Rezolve AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Rezolve AI's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.